欧美一级影片一区二区-免费欧美福利视频-中文字幕亚洲毛片网-91日韩欧美一区二区-欧美高清不卡一区

您好!歡迎訪問(wèn)上海起發(fā)實(shí)驗(yàn)試劑有限公司網(wǎng)站!
全國(guó)服務(wù)咨詢熱線:

15921799099

當(dāng)前位置:首頁(yè) > 資料下載 > BioCheck新產(chǎn)品BC-1303 說(shuō)明書(shū)

BioCheck新產(chǎn)品BC-1303 說(shuō)明書(shū)

發(fā)布時(shí)間:2017/7/31      點(diǎn)擊次數(shù):1086

世界*實(shí)驗(yàn)材料供應(yīng)商 BioCheck正式授權(quán)上海起發(fā)為其中國(guó)代理, BioCheck在一直是行業(yè)的*,一直為廣大科研客戶提供zui為的產(chǎn)品和服務(wù),上海起發(fā)一直秉承為中國(guó)科研客戶帶來(lái)的產(chǎn)品,的服務(wù),簽約 BioCheck就是為了給廣大科研客戶帶來(lái)更加完善的產(chǎn)品和服務(wù),您的滿意將是我們zui大的收獲

 BioCheck中國(guó)代理, BioCheck上海代理, BioCheck北京代理,BioCheck廣東代理, BioCheck江蘇代理BioCheck湖北代理,BioCheck天津,BioCheck黑龍江代理,BioCheck內(nèi)蒙古代理,BioCheck吉林代理,BioCheck福建代理, BioCheck江蘇代理, BioCheck浙江代理, BioCheck四川代理

BIOCHECK公司由創(chuàng)始人 Dr. John Chen, Medix創(chuàng)立, 是一家抓也提供腫瘤標(biāo)志物,心肌標(biāo)志物,激素類zui高性價(jià)比的抗體的公司。
  

簡(jiǎn)要原理

利用競(jìng)爭(zhēng)酶聯(lián)免疫方法,預(yù)先在微孔中包被羊抗兔抗體,實(shí)驗(yàn)時(shí)先后加入氯霉素標(biāo)準(zhǔn)品或待測(cè)樣本,氯霉素酶標(biāo)抗原和兔抗氯霉素抗體。經(jīng)過(guò)室溫溫育,反應(yīng)液中的兔抗氯霉素抗體與微孔板上的羊抗兔抗體結(jié)合,待測(cè)樣品中的抗原與氯霉素酶標(biāo)抗原競(jìng)爭(zhēng)微孔板上的兔抗氯霉素抗體。洗滌后,沒(méi)有與抗

體結(jié)合的待測(cè)樣品中的抗原或酶標(biāo)抗原被洗去,再加入反應(yīng)底物,結(jié)合的酶標(biāo)抗原的酶將底物轉(zhuǎn)化為藍(lán)色產(chǎn)物,加入終止液后顏色由藍(lán)色變?yōu)辄S色。反應(yīng)完成后,樣品中氯霉素含量越多,反應(yīng)呈色就越淺;反之,樣品中氯霉素含量越少,則呈色越深。利用標(biāo)準(zhǔn)曲線可計(jì)算出樣品中氯霉素含量。

技術(shù)參數(shù)

   檢測(cè)蜂蜜、蛋類、牛奶、奶粉、水產(chǎn)品、動(dòng)物組織(肌肉、肝臟等)、飼料、血清、血漿及尿液樣本中存在的氯霉素,定量限可達(dá)0.025 ppb。

No.

樣品

檢測(cè)下限

1

蜂蜜

0.02 ppb (0.02 ng/g)

2

蛋類

0.02 ppb (0.02 ng/g)

3

牛奶

0.002 ppb (0.002 ng/ml)

4

奶粉

0.012 ppb (0.012 ng/g)

5

蝦,魚(yú)及肉類

0.08 ppb (0.08 ng/g)

6

飼料

0.08 ppb (0.08 ng/g)

7

血清/血漿

0.02 ppb (0.02 ng/ml)

8

尿液

0.04 ppb (0.04 ng/ml)

 

交叉反應(yīng)

名稱

百分比

氯霉素堿

0.4%

甲基氯霉素

<0.04%

 

回收率                                        

No.

樣品

回收率

1

蜂蜜

70% ~ 110%

2

牛奶

90% ~ 130%

3

蛋,蝦,魚(yú)及肉類

95% ~ 120%

4

飼料

95% ~ 120%

5

血清 / 血漿

90% ~ 120%

6

尿液

100% ~ 130%

 

PD-L1 ENZYME IMMUNOASSAY TEST KIT

Catalog Number: BC-1303

Enzyme Immunoassay for the Quantitative Determination of PD-L1 Concentration in Human Serum and Plasma

 

FOR RESEARCH USE ONLY

Not for use in diagnostic procedures

INTRODUCTION

Programmed death receptor-ligand 1 (PD-L1, B7- H1, CD274) is a biomarker from the B7 family that is expressed on a variety of cells and upregulated in response to pro-inflammatory cytokines such as interferon gamma1,2,3. PD-L1 interacts with PD-1, a co-receptor expressed by exhausted T cells, to encourage an immunosuppressive tumor microenvironment by decreasing T cell receptor mediated proliferation and cytokine production4, 5. The PD-1/PD-L1 interaction functions as an immune checkpoint in a process known as immunoediting where the host immune system eliminates highly immunogenic tumors while allowing less immunogenic tumor to evade it2, 6. Multiple solid tumor types including melanoma, renal cell carcinoma, non-small cell lung cancer, ovarian, and colorectal cancer utilize this PD-1/PD -L1 immunoediting mechanism2. Current treatment has focused on blocking the PD-1/PD-L1 interaction to reduce tumor evasion by inhibiting PD-1, with new focus on PD-L1 as well1, 2.

PRINCIPLE OF THE ASSAY

The PD-L1 ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a unique monoclonal antibody pair directed against a distinct antigenic determinant on the PD-L1 molecule. One mouse monoclonal anti- PD- L1 antibody is used for solid phase immobilization (on the microtiter wells). Another mouse monoclonal anti-PD-L1 antibody conjugated to horseradish peroxidase (HRP) is in the enzyme conjugate solution. The test samples are allowed to react sequentially with the two antibodies, resulting in the PD-L1 molecules to be sandwiched between the solid phase and enzyme-linked antibodies. After two separate 60- minute incubation steps at room temperature, the wells are rinsed with Wash Buffer to remove unbound labeled antibodies. TMB Reagent is added and incubated for 30 minutes under dark conditions, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution, changing the color to yellow. The concentration of

PD-L1 is directly proportional to the color intensity of the test samples. Absorbance is measured spectrophotometrically at 450 nm.

REAGENTS AND MATERIALS PROVIDED

  • Antibody-Coated Wells (1 plate, 96 wells)

Microtiter wells coated with mouse monoclonal anti-PD-L1

  • 20 ng/ml PD-L1 Standard (0.5 mL /vial)

20 ng/mL PD-L1 in phosphate buffer-BSA solution with preservatives

3. Standard and Sample Diluent (30 mL/bottle, 1 bottle)

Contains phosphate buffer-BSA solution with preservatives

  • Enzyme Conjugate Reagent (12 mL/vial, 1 vial)

Contains mouse monoclonal anti-PD-L1 conjugated to horseradish peroxidase

  • 20X Wash Buffer (50 mL/bottle, 1 bottle) Phosphate buffer with detergents
  • TMB Reagent (11 mL/bottle, 1 bottle)

Contains one-step TMB solution

  • Stop Solution (11 mL/bottle, 1 bottle)

Contains diluted hydrochloric acid (1N HCl)

 

STORAGE CONDITIONS

  • Store the unopened kit at 2-8°C upon receipt and when it is not in use, until the expiration shown on the kit label. Refer to the package label for the expiration date.
  • Keep microtiter plate in a sealed bag with desiccant to minimize exposure to damp air.

REAGENT PREPARATION

  • All reagents should be allowed to reach room temperature (18-25°C) before use.
  • For each test run, prepare a fresh standard set.
  • Dilute 20 ng/mL standard to 5 ng/mL. Prepare two-fold serial dilutions of the 5 ng/mL Standard with Standard/Sample Diluent:
    • 5 ng/mL: 0.15 mL of 20 ng/mL+ 0.45 mL of Standard/Sample Diluent
  • 2.5 ng/mL: 0.25 mL of 5 ng/mL+ 0.25 mL of Standard /Sample Diluent
  • 1.25 ng/mL: 0.25 mL of 2.5 ng/ml + 0.25 mL of Standard/Sample Diluent
  • 0.625 ng/mL: 0.25 mL of 1.25 ng/mL + 0.25 mL of Standard/Sample Diluent
  • 0.313 ng/mL: 0.25 mL of 0.625 ng/mL + 0.25 mL of Standard/Sample Diluent
  • 0.156 ng/mL: 0.25 mL of 0.313 ng/mL + 0.25 mL of Standard Diluent
  • 0.078 ng/mL: 0.25 mL of 0.156 ng/mL + 0.25 mL of Standard Diluent
  • 0 ng/mL: 0.25 mL of Standard Diluent
  • Patient samples need to be diluted 4-fold prior to use. Prepare a series of small tubes (i.e., 1.5 mL microcentrifuge tubes) and mix 60 µL of serum with 180 µLStandard/Sample Diluent.
  • Working Wash Buffer: Preparation of 1X Wash Buffer from 20X Stock. Add 50 mL of 20X Wash Buffer Stock to 950 mL of DI H2O. The Working Wash Buffer is stable at 2-8°C for 30 days. NOTE: Any crystals that may be present due to high salt concentration must be redissolved at room temperature before making the dilution.

ASSAY PROCEDURE

  • Prepare Standards. See Reagent Preparation.
  • Dilute samples 1:4 dilution. See Reagent Preparation.
  • Secure the desired number of coated wells in the holder.
  • Dispense 100 m L of PD-L1 standards, and DILUTED specimens into the appropriate wells.
  • Incubate for 60 minutes at room temperature (18-25 °C).
  • Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 m L Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
  • Dispense 100 m L of PD-L1 Working Enzyme Conjugate Reagent into each well.
  • Incubate for 60 minutes at room temperature (18-25 °C).
  • Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 uL Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
  • Dispense 100 mL TMB solution into each well.
  • Incubate for 30 minutes at room temperature (18-25 °C).
  • Stop the reaction by adding 100 mL of Stop Solution into each well.
  • Gently mix for 30 seconds. It is important to make sure that all the blue color changes to yellow color compley.
  • Read absorbance at 450 nm with a microtiter well reader within 15 minutes.

CALCULATION OF RESULTS

  • Calculate the mean absorbance value (OD450) for each set of reference standards, controls and samples.
  • Construct a standard curve by plotting the mean absorbance obtained for each reference standard against its concentration in ng/ml on graph paper, with absorbance on the vertical (y) axis and concentration on the horizontal (x) axis.
  • The corresponding concentration of PD-L1 (ng/mL) can be determined from the standard curve using the mean absorbance value for each sample. Depending on experience and/or the availability of computer capability, other methods of data reduction may be employed.
  • The obtained values of the samples should be multiplied by the dilution factor of 4 to obtain PD-L1 results in ng/ml.

EXAMPLE OF STANDARD CURVE

Results of a typical standard run with absorbency readings at 450 nm shown on the Y axis against PD-L1 concentrations shown on the X axis. NOTE: This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each laboratory must generate its own data and standard curve in each experiment.

 

PD-L1

Absorbance

(ng/ml)

(450 nm)

0

0.042

0.078

0.141

0.156

0.236

0.313

0.415

0.625

0.726

1.25

1.283

2.5

2.100

5

3.053

 

nm

3.5

 

 

 

 

 

3

 

 

 

 

 

(450

 

 

 

 

 

2.5

 

 

 

 

 

2

 

 

 

 

 

Absorbance

 

 

 

 

 

1.5

 

 

 

 

 

1

 

 

 

 

 

0.5

 

 

 

 

 

0

 

 

 

 

 

 

0

1

2

3

4

5

 

 

 

PD-L1 Conc. (ng/ml)

 

 

PERFORMANCE CHARACTERISTICS

  • Sensitivity

The minimum detectable concentration of the PD-L1 ELISA assay as measured by 2SD from the mean of a zero standard is estimated to be 0.02 ng/ml.

  • Precision
  • Intra-Assay Precision

Within-run precision was determined by replicate determinations of three different samples in one assay. Within-assay variability is shown below:

 

Sample

1

2

3

# Replicates

24

24

24

Mean PD-L1 (ng/mL)

1.5

3.0

7.4

S.D.

0.04

0.05

0.18

C.V. (%)

2.4%

1.6%

2.4%

2

  • Inter-Assay Precision

Between-run precision was determined by replicate measurements of three different samples over a series of individually calibrated assays. Between-assay variability is shown below:

 

Sample

1

2

3

# Replicates

20

20

20

Mean PD-L1 (ng/mL)

1.6

3.0

7.4

S.D.

0.04

0.12

0.26

C.V. (%)

2.5%

4.1%

3.5%

 

  • Recovery and Linearity Studies

 

  • Recovery

Samples were spiked with known PD-L1 levels and assayed in duplicate. The mean recovery was 90%.

 

Sample

EXPECTED

OBSERVED

% RECOVERY

 

[PD-L1]

[PD-L1]

 

 

(ng/mL)

(ng/mL)

 

1

2

1.8

90%

2

5

4.6

92%

3

10

8.9

89%

 

  • Linearity

Three samples were serially diluted to determine linearity. The mean recovery was 110.3%.

 

#

Dilution

Expected

Observed

 

 

 

Conc. (ng/ml)

Conc. (ng/ml)

% Expected

1.

1:4

1.6

1.6

N/A

 

1:8

 

1.7

106.3%

 

1:16

 

1.7

106.3%

 

1:32

 

1.8

112.5%

 

 

 

 

Mean = 108.4%

2.

1:4

3.7

3.7

N/A

 

1:8

 

4.0

108.1%

 

1:16

 

4.0

108.1%

 

1:32

 

4.1

110.8%

 

 

 

 

Mean = 109.0%

 

 

 

 

 

3.

1:4

7.4

7.4

N/A

 

1:8

 

8.3

112.2%

 

1:16

 

8.6

116.2%

 

1:32

 

8.3

112.2%

Mean = 113.5%

REFERENCES

 

  • Herbst, Roy S., et al. "Predictive correlates of response to the

anti-PD-L1 antibody MPDL3280A in cancer

patients." Nature 515.7528 (2014): 563.

  • Pa, Sandip Pravin, and Razelle Kurzrock. "PD-L1 expression as a predictive biomarker in cancer immunotherapy." Molecular cancer therapeutics 14.4 (2015): 847-856.
  • Topalian, Suzanne L., Charles G. Drake, and Drew M. Pardoll. "Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity." Current opinion in immunology 24.2 (2012): 207-212.
  • Blank, Christian, and Andreas Mackensen. "Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion." Cancer immunology, immunotherapy 56.5 (2007): 739-745.
  • Barber, Daniel L., et al. "Restoring function in exhausted CD8 T cells during chronic viral infection." Nature 439.7077 (2006): 682.
  • Teng, Michele WL, et al. "Classifying cancers based on T-cell infiltration and PD-L1." Cancer research 75.11 (2015): 2139-2145.

 

部分產(chǎn)品如下:

貨號(hào)品名Tests/Kit規(guī)格品牌
70748Mouse Monoclonal anti-human PD-1 (Capture)Purified0.1/0.5/1 mgBioCheck
70749Mouse Monoclonal anti-human PD-1 (Capture)Purified0.1/0.5/1 mgBioCheck
70750Mouse Monoclonal anti-human PD-1 (Detection)Purified0.1/0.5/1 mgBioCheck
70751Mouse Monoclonal anti-human PD-L1 (Capture)Purified0.1/0.5/1 mgBioCheck
70752Mouse Monoclonal anti-human PD-L1 (Capture)Purified0.1/0.5/1 mgBioCheck
70753Mouse Monoclonal anti-human PD-L1 (Detection)Purified0.1/0.5/1 mgBioCheck
70745Mouse monoclonal anti-human Lp-PLA2 (Capture)Purified0.5 mgBioCheck
70746Mouse monoclonal anti-human Lp-PLA2 (Detection)Purified0.5 mgBioCheck
70747Mouse monoclonal anti-human Lp-PLA2 (Detection)Purified0.5 mgBioCheck

 

我們公司zui大優(yōu)勢(shì)是強(qiáng)大的采購(gòu),

1:基本什么都能進(jìn)口,血清,抗體,耗材,還有部分限制進(jìn)口的,

2:貨品全,現(xiàn)經(jīng)營(yíng)過(guò)700多個(gè)品牌,基本所有生物試劑耗材都可以進(jìn)口,特別是冷偏的產(chǎn)品那就更有優(yōu)勢(shì),

3:提供加急服務(wù),一般1-2周到貨,超過(guò)時(shí)限加急費(fèi)全免

4:價(jià)格公道,絕大部分價(jià)格有優(yōu)勢(shì),當(dāng)然不能保證100%產(chǎn)品都是,因?yàn)橐馕吨鴽](méi)有服務(wù).

5:良好的信譽(yù),大部分客戶我們提供貨到付款服務(wù),客戶包括清華,北大 交大 復(fù)旦,中山等100多所大學(xué),ROCHE,阿斯利康,國(guó)藥 ,fisher等500多家公司

6:我們*代理的品牌有:Antibody Research Corporation,arcticzymes,Biorelevant,AmberGen, Inc. ,clemente-associates,clodronaiposomes,Columbia Biosciences,enzyme research,Gene Bridges GmbH,Genovis,AmberGen, Inc.  Biotechnology GmbH,Haematologic Technologies HTI Haemtech,hookelabs,Immudex,Innovative Research of America,inspiralis ,List Biological Laboratories, Inc.,lumafluor,Microsurfaces,multiplicom,nanotools,Pel-Freez Biologicals,pentapharm,progen,Protein Ark,QA-Bio,Inc,QA-Bio,IncQuickZyme Biosciences,Teknova,TriLink BioTechnologies, Inc.,Zyagen Laboratories 等

7:我們還是invitrogen,qiagen,Midland BioProducts Corporationam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等知名*批發(fā),歡迎合作。


文件下載    
上海起發(fā)實(shí)驗(yàn)試劑有限公司
地址:上海浦東川沙鎮(zhèn)川沙路6619號(hào)上海起發(fā)實(shí)驗(yàn)試劑有限公司
郵箱:xs1@78bio.com
傳真:021-50724961
關(guān)注我們
歡迎您關(guān)注我們的微信公眾號(hào)了解更多信息:
歡迎您關(guān)注我們的微信公眾號(hào)
了解更多信息